Cellectis Stock Surges 5.83% Midday After Weeks of Decline

Technical Signals and Market Position

This Tuesday, Cellectis is trading at 3.45 euros, a level that almost exactly coincides with its 20-day moving average, now at 3.35 euros, which it has now crossed upwards. This crossing represents a significant technical signal after several weeks of consolidation. However, the stock remains below its 50-day moving average, set at 3.52 euros, which acts as immediate resistance. The RSI, an indicator measuring buying and selling momentum, stands at 49, indicating a neutral zone that reflects neither bullish nor bearish excess. The stock price is in the median part of its Bollinger Bands, ranging from 3.08 euros (lower bound) to 3.61 euros (upper bound), confirming the absence of marked directional tension. Over one year, the stock still maintains a remarkable performance of 174.7%, reflecting the progress made by the stock since the levels of March 2025.

Wider Market Movements

Cellectis' rise today is part of a broader rebound across European markets. The CAC 40 is up 2.16% in the session, while the German DAX has advanced 2.22% and the London FTSE 100 has increased by 1.67%. In Asia, the Nikkei 225 closed up 2.88% and the Hang Seng gained 2.17% at the day's close. However, this renewed appetite for risk assets comes in a context of high tension, with the VIX — the American market volatility index — standing at 29.49 points on March 6, a jump of more than 24% from the previous day. This level, significantly above the historical average, signals still unstable market conditions. For the biotech specialized in gene editing and cellular therapies, the monthly volatility reaches 17.44%, while its negative beta of -0.39 indicates an inverse correlation with the market, making this Tuesday's synchronous rebound all the more notable.